CRON.TO - Cronos Group Inc.
| Previous Close | 8.98 |
| Open | 9.09 |
| Bid | 9.62 x 0 |
| Ask | 9.65 x 0 |
| Day's Range | 8.98 - 9.66 |
| 52 Week Range | 7.97 - 32.95 |
| Volume | 1182518 |
| Avg. Volume | 928,269 |
| Market Cap | 3.3B |
| Beta (5Y Monthly) | 3.77 |
| PE Ratio (TTM) | 7.17 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Water Ways Completes Installation of the First Cannaways Irrigation and Fertilization System at the Cronos Facility in Israel
Cannaways is an Internet of Things (“IoT”) controlled irrigation and fertilization system for cannabis cultivators and growers. The Cannaways system is uniquely designed for the specific needs of cannabis growers and cultivators worldwide, in order to increase the yield and consistency of high-quality cannabis while reducing energy, water, and fertilization costs. The Cannaways system is also available for greenhouse, outdoor food production and fish farm operations where controlled irrigation and fertilization systems are desired.
- GlobeNewswire
Cronos Group Inc. Announces Third Quarter 2019 Results
Closed Redwood U.S. Hemp-Based Products Platform and Cronos Fermentation Facility Acquisitions Announced the launch PEACE+™, A New Hemp-Derived U.S. Brand Advanced Operational.
- GlobeNewswire
Cronos Group Issues Statement on Separately Announced Closing of the IPO of Cronos Australia
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) today noted the separately announced closing of the AUD$20 million initial public offering of Cronos Australia Limited (“Cronos Australia”). Under the offering, Cronos Australia issued 40 million new shares at an offering price of AUD$0.50 per share (the “Cronos Australia IPO”). Cronos Australia expects to start trading on the Australian Securities Exchange on a deferred settlement basis on November 7, 2019.
- GlobeNewswire
Cronos Group Issues Statement on Separately Announced IPO of Cronos Australia
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) today noted the separately announced AUD$20 million initial public offering of Cronos Australia Limited (“Cronos Australia”). Under the offering, Cronos Australia is expected to issue 40 million new shares at an offering price of AUD$0.50 per share (the “Cronos Australia IPO”) ahead of its planned listing on the Australian Securities Exchange in November 2019. Established in February 2018, Cronos Australia is a 50/50 joint venture between Cronos Group and NewSouthern Capital Pty Ltd., and is led by Rodney Cocks and Peter Righetti. The launch marked a significant milestone in Cronos Group’s commitment to advancing cannabis research and producing and distributing products and brands at a global scale.
- GlobeNewswire
Cronos Group Inc. to Hold Third Quarter 2019 Earnings Conference Call
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) will announce its financial results for the third quarter ended September 31, 2019 and hold its Third Quarter 2019 Earnings Conference Call on Tuesday, November 12, 2019 at 8:30 a.m. EDT. A live audio webcast of the earnings call will be available on the Company’s website at https://ir.thecronosgroup.com/events-presentations. The call will be archived on the Company’s website for replay.
- GlobeNewswire
Cronos Group Announces Appointment of Jody Begley to Board of Directors
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) today announced that, in connection with its investment in the Company, Altria Group, Inc. (“Altria”) has appointed Jody Begley to the Cronos Group Board of Directors. Mr. Begley is currently Senior Vice President, Tobacco Products for Altria Group in which he oversees more than $24 billion in net revenues.
- GlobeNewswire
Cronos Group Inc. CEO, Mike Gorenstein, to Present at the CIBC 18th Annual Eastern Institutional Investors Conference
Cronos Group Inc. (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and Chief Executive Officer, will speak at the CIBC 18th Annual Eastern Institutional Investors Conference on Wednesday September 25, 2019 at 3:25 p.m. ET in Montreal, QC. The presentations will be available on the Investors section of the Company’s website at ir.thecronosgroup.com/events-presentations.
- GlobeNewswire
MediPharm Labs and Cronos Group Enter Private Label Contract Manufacturing Agreement
MediPharm Labs Corp. (TSX:LABS) (MEDIF) (MLZ.F) (“MediPharm Labs” or the “Company”), a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that it has signed a multi-year contract manufacturing agreement (“CMA”) for the filling and packaging of vaporizer devices, subject to approval by Health Canada, for Cronos Group Inc.’s (CRON.TO) (CRON.TO) (“Cronos Group”) adult-use brand, COVE™. MediPharm Labs Inc. (“MediPharm”), a wholly-owned subsidiary of the Company, and a wholly-owned subsidiary of Cronos Group, entered into a CMA where MediPharm, utilizing its proprietary expertise and equipment, will provide filling of high-quality formulated concentrate, labelling and packaging services to exacting specifications at scale for Cronos Group.
- GlobeNewswire
Cronos Group Inc. CEO, Mike Gorenstein, to Present at Barclays 2019 Global Consumer Staples Conference
Cronos Group Inc. (“Cronos Group” or the “Company”) (CRON.TO) (CRON.TO), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and Chief Executive Officer of Cronos Group, will speak at Barclays Global Consumer Staples Conference at 10:30 a.m. ET in Boston, MA. The presentation will be available on the Investors section of the Company’s website at ir.thecronosgroup.com/events-presentations.
- GlobeNewswire
Cronos Group Inc. Enters into Credit Agreement with Cronos Growing Company Inc.
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) has entered into a credit agreement (the “Credit Agreement”), as administrative agent and lender, with Cronos Growing Company Inc. (“Cronos GrowCo” or “GrowCo”), as borrower, in respect of a $100 million secured non-revolving term loan credit facility (the “Credit Facility”).
- GlobeNewswire
Cronos Group Inc. Announces Second Quarter and First-Half 2019 Results
Opened Cronos Device Labs, New Global R&D Center in Israel Appointed Dr. Todd Abraham as Chief Innovation Officer Announced Agreement to Acquire.
- GlobeNewswire
Cronos Group Establishes New Growth Opportunity in the United States with Acquisition of Hemp-Based Products Platform
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) today announced that it has entered into a definitive agreement to acquire four of Redwood Holding Group, LLC’s operating subsidiaries (collectively, “Redwood”). Redwood manufactures, markets and distributes hemp-derived cannabidiol (CBD) infused skincare and other consumer products online and through retail and hospitality partner channels in the United States under the brand, Lord Jones™. Redwood was co-founded in 2017 by Robert Rosenheck and Cindy Capobianco.
- GlobeNewswire
Cronos Group Enters Agreement to Acquire State-of-the-Art Fermentation and Manufacturing Facility
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) today announced that it has entered into an agreement to acquire an 84,000 square foot GMP compliant fermentation and manufacturing facility in Winnipeg, Canada from Apotex Fermentation Inc. (“AFI”). As previously announced, Cronos Group has entered into a partnership with Ginkgo Bioworks, Inc. (“Ginkgo”) to produce cultured cannabinoids.
- GlobeNewswire
Cronos Group Appoints Dr. Todd Abraham as Chief Innovation Officer
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) today announced that Dr. Todd Abraham has been appointed as the Company’s Chief Innovation Officer. In this role, Dr. Abraham will be responsible for advancing Cronos Group’s research and development initiatives in cannabinoids with a focus on identifying new disruptive technologies and adopting best practices and innovations from adjacent consumer goods industries.
- GlobeNewswire
Cronos Group Inc. to Hold Second Quarter 2019 Earnings Conference Call
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”), will announce its financial results for the second quarter ended June 30, 2019, and hold its Second Quarter 2019 Earnings Conference Call on Thursday, August 8, 2019 at 8:30 a.m. EDT. A live audio webcast of the earnings call will be available on the Company’s website at https://ir.thecronosgroup.com/events-presentations. The call will be archived on the Company’s website for replay.
- GlobeNewswire
Cronos Group Inc. Announces Results of Vote for Election of Directors
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) reports that at its Annual Meeting of Shareholders on June 19, 2019 there were 610 shareholders voting in person or by proxy holding in total 261,290,314 common shares, representing 78.2% of the total number of common shares outstanding.
- GlobeNewswire
Cronos Group Inc. to Present at Piper Jaffray 39th Annual Consumer Marketplace Conference, Jefferies 2019 Healthcare Conference and Stifel 2019 Cross Sector Insight Conference
Cronos Group Inc. (“Cronos Group” or the “Company”) (CRON.TO) (CRON.TO), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and Chief Executive Officer, will speak at three industry conferences in June. Mr. Gorenstein will present at the Piper Jaffray 39th Annual Consumer Marketplace Conference on Thursday June 6, 2019 at 1:30 p.m. ET in New York, NY, the Jefferies 2019 Healthcare Conference on Friday June 7, 2019 at 11:30 a.m. ET in New York, NY and the Stifel 2019 Cross Sector Insight Conference on Wednesday June 12, 2019 at 1:15 p.m. ET in Boston, MA. The presentations will be available on the Investors section of the Company’s website at ir.thecronosgroup.com/events-presentations.
- GlobeNewswire
Cronos Group Inc. Sets Date for 2019 Annual Meeting of Shareholders
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, will hold its 2019 Annual Meeting of Shareholders on Wednesday, June 19, 2019 at 10 a.m. ET at the offices of Blake, Cassels & Graydon LLP located at 199 Bay Street, Suite 4000, Commerce Court West, Toronto. The Notice of Meeting and Management Information Circular are available on the Governance section of the Company’s website at https://ir.thecronosgroup.com/investor-relations. A live audio webcast and replay of the meeting will also be available in the Investor Relations section of the Company’s website.
- GlobeNewswire
Cronos Group and MediPharm Labs Enter $30 Million Multi-Year Private Label Cannabis Concentrate Supply Agreement with Potential to Increase to $60 Million
MediPharm Labs Corp. (LABS.V) (MEDIF) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that it has entered into a multi-year supply agreement with Cronos Group Inc. (CRON) (CRON) (“Cronos Group”). MediPharm Labs will supply Cronos Group with approximately $30 million of high-quality private label cannabis concentrate over 18-months, and, subject to certain renewal and purchase options, potentially up to $60 million over 24-months. In addition, Cronos Group has selected MediPharm Labs’ state of the art extraction facility in Barrie, Ontario, as a preferred partner to fulfill certain of its processing needs, under a separate tolling arrangement.
- GlobeNewswire
Cronos Group and MediPharm Labs Enter Cannabis Concentrate Supply Agreement
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”), is pleased to announce that it has entered into a multi-year supply agreement with MediPharm Labs Corp. (LABS.V) (MEDIF) (“MediPharm Labs”). MediPharm Labs will supply Cronos Group with approximately $30 million of high-quality private label cannabis concentrate over 18-months, and, subject to certain renewal and purchase options, potentially up to $60 million over 24-months.
- GlobeNewswire
Cronos Group Inc. Announces First Quarter 2019 Results
Cronos Group Closes C$2.4 Billion Strategic Investment from Altria Group Cronos Group Establishes Cronos Device Labs, a State-of-the-Art Vaporizer R&D Initiative NatuEra.
- GlobeNewswire
Cronos Group Opens Cronos Device Labs, New Global R&D Center in Israel
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) today announced that it is expanding its global infrastructure network and innovation capabilities with the opening of a cannabinoid device R&D facility, based in Israel (“Cronos Device Labs”). The state-of-the-art facility supports Cronos Group’s efforts to develop next-generation vaporizer products that are designed specifically for cannabinoid applications. Cronos Device Labs, which is equipped with an experienced team of product development talent, advanced vaporizer technology and analytical testing infrastructure, serves as the global center of R&D for the Company’s vaporizer devices.
- GlobeNewswire
Water Ways Reports Fiscal Year 2018 Financial Results
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, May 02, 2019 -- Water Ways Technologies Inc. (TSXV: WWT) ("Water Ways" or the.
- CNW Group
Hemp Boom Spawns Lucrative Deals
DENVER , April 17, 2019 /CNW/ -- Ever since the Farm Bill was signed into law, farmers across the United States have rushed into hemp cultivation, driving demand for the supplies needed to grow the crop necessary to meet surging CBD use. Global hemp industry to reach $22 billion in 2022. Hemp is booming across the country, and nowhere more so than in Kentucky , where the applications to grow hemp are expected to increase fivefold, and acreage dedicated to growing the crop is set to more than triple this year.
- GlobeNewswire
Water Ways Provides Business and Expansion Update From CEO Ohad Haber
Water Ways Technologies Inc. (WWT.V) ("Water Ways" or the "Company"), is pleased to provide a business update from the Company's founder and chief executive officer Mr. Ohad Haber. On behalf of the Company I wish to thank you for your support.